AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC 50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC 50 of 32 μM. AMG-208 has anti-cancer activity.
性状
Solid
IC50 & Target[1][2]
CYP3A4 32 μM (IC50) c-Met 9 nM (IC50
体外研究(In Vitro)
AMG-208 (compound 4) treatment also leads to the inhibition of HGF-mediated c-Met phosphorylation in PC3 cells with IC50 of 46 nM. Pre-incubation of AMG-208 (compound 1) with human liver microsomes for 30 minutes shows a potent time-dependent inhibition for CYP3A4 metabolic activity with IC50 of 4.1 μM, which is an eightfold decrease relative to the IC50 (32 μM) without preincubation. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
In male Sprague Dawley rats, AMG-208 (0.5 mg/kg i.v.) shows a high bioavailability with Cl of 0.37 L/h/kg, Vss of 0.38 L/kg and T1/2 of 1 hour. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51(10), 2879-2882.[2]. Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19(22), 6307-6312.
溶解度数据
In Vitro: DMSO : 3.33 mg/mL (8.69 mM; Need ultrasonic)配制储备液